PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

Biotechnology

Healthcare
$1.22 +3.91%

+$0.04 today

Market cap
$65.06M
Beta
1.36
P/E (TTM)
-0.8
EPS (TTM)
-$1.47
52W Low $0.96High $1.88

Volume 0.43M

Average 0.38M

PMVP Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

PMV Pharmaceuticals, Inc.NASDAQ: PMVP

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 53.33M shares rose 2.7% year over year, in line with the +2.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2.7% holds above the trailing-twelve-month pace of +2.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
53.33M+0.1% QoQ
Last fiscal yearDec 2025
52.54M+1.9% YoY
LTMMar 2026
52.9M+2.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.7%——
1 year+1.9%——
3-year CAGR+4.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
52.54M USD
Year-over-year change
+1.9%
4-year CAGR
+3.9%

Weighted Avg Shares (Diluted) vs competitors

How PMVP compares with its peers on the latest reported figures

  • PMVP's LTM Mar 2026 weighted avg shares (diluted) of 52.9M shares is the 7th highest of the 9 companies compared; the peer median is 76.15M shares.
  • Its year-over-year change of +2.4% is the 8th highest of 9, against a peer median of +38.2%.
  • Over three fiscal years its annual growth of +4.8% compares with a peer median of +21.0%.
PMVP Competitors Peer median
Weighted Avg Shares (Diluted) for PMVP and competitors
Company Period LTM YoY 3-year CAGR
CBUSCibus, Inc.LTM Mar 2026301.04M +1164.8%-7.5%
VXRTVaxart, Inc.LTM Mar 2026232.46M +14.7%-22.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
ATYRaTyr Pharma, Inc.LTM Mar 202695.83M +20.8%+48.5%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
Peer median (excluding PMVP) 76.15M+38.2%+21.0%

Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.28M650K1.26M1.14M0
Gross Profit(1.28M)(650K)(1.26M)(1.14M)0
Gross Margin—————
Research & Development36.19M51.67M54.63M57.38M69.88M
Selling, General & Admin20.83M24.72M24.25M26.92M16.33M
Operating Expenses57.01M76.39M78.88M84.3M86.21M
Depreciation & Amortization1.28M650K1.26M1.14M133K
EBITDA(56.54M)(72.68M)(67.7M)(73.67M)(79.78M)
EBITDA Margin—————
Operating Income(58.29M)(77.04M)(80.13M)(85.45M)(86.21M)
Operating Margin—————
Interest Income449K3.63M11.17M10.66M6.34M
Interest Expense00000
Other Income / Expenses470K3.71M11.17M10.64M6.29M
Income Before Tax(57.82M)(73.33M)(68.96M)(74.81M)(79.91M)
Pre-Tax Margin—————
Income Tax Expense23K(9K)2K(16.1M)(2.17M)
Net Income(57.85M)(73.32M)(68.96M)(58.71M)(77.74M)
Net Margin—————
EPS (Basic)(1.28)(1.61)(1.44)(1.14)(1.48)
EPS (Diluted)(1.28)(1.61)(1.44)(1.14)(1.48)
Weighted Avg Shares45.14M45.59M48.01M51.58M52.54M
Weighted Avg Shares (Diluted)45.14M45.59M48.01M51.58M52.54M

PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

Intrinsic Alpha fair value

Locked

Current Price

$1.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.